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Introduction: Histiocytic sarcoma is a rare neoplasm with few cases reported in the literature of which some were
diagnosed in animals. This neoplasm arises from abnormal reticuloendothelial system cell proliferation of histiocytes
and has an aggressive behavior especially if located in the central nervous system. We present the first case of a
patient with histiocytic sarcoma that involved the meninges and had a good course after multidisciplinary
treatment.
Case presentation: Our patient was a 41-year-old Caucasian woman with no previous history of disease who
started with systemic symptoms such as headache and chills. Magnetic resonance imaging with gadolinium
contrast of the brain suggested a mass 1.5×2cm in diameter in the temporal lobe with a non-uniform vasogenic
edema. This lesion was implanted in the meninges and surgery was the first treatment. The histological findings
revealed a histiocytic sarcoma. The patient received concomitant chemoradiotherapy after surgery with good
tolerance and currently lives without disease.
Conclusion: Although histiocytic sarcomas in the brain present an unusual location and have a poorer prognosis,
we have identified the first primary leptomeningeal histiocytic sarcoma with a disease-free survival greater than 3
years following multidisciplinary treatment with surgery and chemotherapy and radiotherapy.
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Histiocytic sarcoma (HS) is a rare neoplasm showing
evidence of histiocytic differentiation. It often appears in
the skin, lymph nodes, and intestinal tract but central
nervous system (CNS) involvement is rare. The standard
treatment for these sarcomas is surgery. The best option
for treating these tumors is unclear and affected patients
have a poor prognosis despite treatment.
Case presentation
In June 2009, a 41-year-old Caucasian woman with no
previous history of illness went to the Emergency Room
with systemic symptoms, including headache, generalized
weakness, and chills. The physical examination showed
nothing remarkable. The workup included a computed* Correspondence: elperu@hcs.es
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distribution, and reproduction in any mediumtomography (CT) brain scan without contrast that showed
nothing unusual. The patient received empirical treatment
for a diagnosis of a suspected viral infection. A week later,
she presented with dysphasia and deviation of the right
corner of her mouth. Magnetic resonance imaging
(MRI) with gadolinium contrast of the brain suggested a
mass 1.5×2cm in diameter in the temporal lobe with a
non-uniform vasogenic edema. This lesion was implanted
in the meninges and indicated possible meningioma
(Figure 1). There was no evidence of malignancy on chest,
abdominal or pelvic CT. In July, left frontal craniotomy
surgery was performed. It showed a meningeal lesion in
the dura mater extending to nearby tissue. The lesion
was excised in its entirety (Figure 2A). The histological
finding described a lesion in the meninges with a diameter
of 3×2cm. The histological findings also revealed a diffuse
non-cohesive proliferation of neoplastic cells that looked
like a histiocyte. The cells were variable in size, with
large and abundant foamy eosinophilic cytoplasm. Thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Magnetic resonance imaging demonstrating meningeal involvement and possible neoplastic disease. From left to right: Axial
T1 image, coronal T1 image, and axial T2 image.
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cytosis by tumor cells. The nuclei were irregular and large
with mono- or multi-nucleation displaying a vacuole
appearance with granular chromatin. It frequently presented
prominent eosinophilic nucleoli. There was a lymphocyte
and neutrophil inflammatory background (Figure 2B). The
entire lesion was neoplastic. The pathologist suggested
a lymphoma but an immunohistochemistry study was
done the results of which showed positive expression ofFigure 2 Histologícal findings. A. Laminar fragment corresponding to d
proliferation of neoplastic cells that look like a histiocyte. The cells are varia
There is a lymphocyte and neutrophil inflammatory background showing n
expression of CD68 in tumor cells.CD68 (Figure 2C), CD163 and lysozyme consistent with
histiocytic lineage and weak expression of S100. The cells,
however, presented negative expression of cytokeratin,
B or T cells, and myeloid markers, including anaplastic
lymphoma kinase 1 (ALK-1), CD3, CD4, CD8, CD20,
CD21, CD23, CD30, CD1a, Bcl2, Bcl6, CD15, CD31 and
CD10. The polymerase chain reaction study did not
show clonal B or T cells. After these results, the path-
ologist diagnosed a HS. We presented the case in theura mater (right) on which arises the tumor. B. Diffuse non-cohesive
ble in size, with irregular nuclei and a strikingly large central nucleus.
umerous neutrophils and phagocytosis by tumor cells. C. Positive
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treatment with chemoradiotherapy: temozolomide (120mg
daily) concomitant with 1.8Gy of radiotherapy 5 days a
week. The radiotherapy was intensity-modulated radiation
therapy guided by imaging: planning target volume (PTV)
1 received 45Gy, PTV2 received 54Gy and PTV3 61.2Gy.
The patient remains disease free after 42 months.
Discussion
HS also formerly known as “true” histiocytic lymphoma is
a rare neoplasm showing evidence of histiocytic differenti-
ation. It often appears in the skin, lymph nodes, and intes-
tinal tract [1]. Although CNS involvement is rare, there are
a few cases reported in the literature [1-5] and other cases
diagnosed in animals, such as cats, dogs, and camels [6-9].
The cases involving the CNS occurred by continuation of
the disease except the case reported by Torres et al. [5]
which appeared in the subarachnoid space.
HS has often been classified as being similar to diseases
such as malignant histiocytosis, histiocytic lymphoma, and
reticular sarcoma, based on morphological criteria [10].
However, advances in molecular and biological markers
have improved immunohistochemistry findings, allowing
for differentiation between HS and B or T cells and non-
Hodgkin lymphomas. These diseases have a prognosis and
treatment different from sarcomas.
HS is composed of mononuclear tumor cells with large
cytoplasmic vacuoles. Some cells present with phagocytosis
phenomena. The diagnosis is based on immunohistochem-
istry markers of histiocytic cells such as positive CD68,
lysozyme, α1-antitrypsin and CD163, which is regarded as
a specific HS marker [11]. However, HS presents negative
markers of epithelial (epithelial membrane antigen or
cytokeratin), melanocytic (CD34 or myeloperoxidase) and
lymphoid (CD3 or CD20) neoplasms as in our case.
Markers of Langerhans cell (CD1a), follicular dendritic
cells, B cells, T cells, and myeloid cells are negative. Lack
of expression of CD30 and ALK-1 excludes anaplastic
large cell lymphoma, which is an important differential
diagnosis. The focal staining for S-100 protein is not
uncommonly seen in the true histiocytic lymphomas as
reported in the literature [12].
Radiological findings have not been established due to
the low number of cases. The HS image study reported
in the literature addressing the brain is MRI [7], which
describes the extent of the disease. The images point
towards neoplastic disease, but there are no specific
images suggesting HS. Some MRI studies in dogs are
inconclusive because the image presented could be either
a benign process (such as encephalitis) or a malignant
process (such as meningioma) [6].
The standard treatment for these sarcomas is surgery.
The best option for treating these tumors is unclear.
Furthermore, when the tumor is located in the CNS thetherapeutic options are reduced. Brain sarcomas have an
aggressive course with an overall survival rate of around
4 to 5 months, regardless of treatment. There are no studies
where the benefit of radiotherapy or chemotherapy for HS
has been established.
In our case, the patient received concomitant chemo-
radiotherapy after surgery. We decided to administer
temozolomide with the radiotherapy because the patient
was young and she presented with a sarcoma affecting
the CNS. It is also known that this type of chemotherapy
crosses the blood–brain barrier and it has shown benefit
over radiotherapy alone in other aggressive tumors [13].
She had a good tolerance and currently lives without
disease (disease-free interval of 42 months). The cases
reported before were treated with different schedules of
chemotherapy by the vein or with intrathecal treatment
but none received concomitant radiotherapy. All the
cases had an aggressive course except one case that
relapsed after 3 years [1]. In the literature, some cases of
extranodal HS treated with surgery and some type of
chemotherapy or radiotherapy had a good outcome. These
reported patients lived varying months after treatment
[14]. Recently, a radiotherapy-induced HS has been
treated with radiation alone and the patient remained
free of recurrent disease after 1.5 years [15]. Radiation
alone could be beneficial but we do not know whether
radiation-induced HS differ in their biological behavior.
Conclusion
In conclusion, HS is a rare neoplasm with a diagnosis
based on immunohistochemistry and biological findings.
Although HS in the brain present an unusual location
and have a poorer prognosis, we have identified the first
primary leptomeningeal HS with a disease-free survival
greater than 3 years following treatment with surgery
and chemotherapy and radiotherapy.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EPR and AR analyzed and interpreted the patient data regarding the
sarcoma histiocytic disease and the treatment. AS performed the histological
examination of the brain, and was a major contributor in writing the
manuscript. MD and AMS treated the patient. All authors read and approved
the final manuscript.
Author details
1Division of Medical Oncology, REDISSEC, Hospital Costa del Sol, Autovía A-7,
Km 187, C.P. 29603, Marbella, Spain. 2Pathology Department, Hospital
Universitario Carlos Haya, Málaga, Spain. 3Division of Radiotherapy Oncology,
Clinic Croasa, Málaga, Spain.
Pérez-Ruiz et al. Journal of Medical Case Reports 2013, 7:127 Page 4 of 4
http://www.jmedicalcasereports.com/content/7/1/127Received: 3 January 2013 Accepted: 11 April 2013
Published: 13 May 2013
References
1. Cheuk W, Walford N, Lou J, Lee AK, Fung CF, Au KH, Mak LS, Chan JK:
Primary histiocytic lymphoma of the central nervous system. Am J Surg
Pathol 2001, 25:1372–1379.
2. Cao M, Eshoa C, Schultz C, Black J, Zu Y, Chang CC: Primary central
nervous system histiocytic sarcoma with relapse to mediastinum.
Arch Pathol Lab Med 2007, 131:301–305.
3. Sun W, Nordberg M, Fowler M: Histiocytic sarcoma involving the central
nervous system. Am J Surg Pathol 2003, 27:258–265.
4. Colovic N, Jurisic V, Colovic M: Malignant histiocytosis with central
nervous system involvement and hepatic mucinous cystadenoma in a
single patient with review of the literature. J BUON 2007, 12:539–542.
5. Torres CF, Korones D, Powers J, Vadasz AG: Primary leptomeningeal
histiocytic lymphoma in a young child. Med and Pediat Oncology 1996,
27:547–550.
6. Molenaar FM, Breed EJ, Flach I, McCandlish IA, Pocknell AM, Strike T, Routh
A, Taema M, Summers BA: Brain tumours in two Bactrian camels: a
histiocytic sarcoma and a meningioma. Vet Rec 2009, 164:684–688.
7. Tamura S, Tamura Y, Nakamoto Y, Ozawa T, Uchida K: MR imaging of
histiocytic sarcoma of the canine brain. Vet Radiol Ultrasound 2009,
50:178–181.
8. Uchida K, Morozumi M, Yamaguchi R, And TS: Diffuse leptomeningeal
malignant histiocytosis in the brain and spinal cord of a Tibetan Terrier.
Vet Pathol 2001, 38:219–222.
9. Ide T, Uchida K, Tamura S, Nakayama H: Histiocytic sarcoma in the brain of
a cat. J Vet Med Sci 2010, 72:99–102.
10. Hirose S, Shimada S, Takebe Y, Tokuriki Y, Kawano H, Kubota T: Recurrent
malignant histiocytosis with cerebrospinal involvement. Neurol Med Chir
1994, 34:233–236.
11. Vos JA, Abbdondanzo SL, Barekman C, Andriko JW, Miettinen M, Aguilera
NS: Histiocytic sarcoma: a study of five cases including the histiocyte
marker CD163. Mod Pathol 2005, 18:693–794.
12. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, Favera RD,
Delsol G, De Wolf-Peeters C, Falini B, Gascoyne RD, Gaulard P, Gatter KC,
Isaacson PG, Jaffe ES, Kluin P, Knowles DM, Mason DY, Mori S, Müller-
Hermelink HK, Piris MA, Ralfkiaer E, Stein H, Su IJ, Warnke RA, Weiss LM:
Tumours of histiocytes and accessory dendritic cells: an
immunohistochemical approach to classification from the International
Lymphoma Study Group based on 61 cases. Histopathology 2002, 41:1–29.
13. Stupp R, Mason WP, Van den Bent M, Weller M, Fisher B, Taphorn MJ,
Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC,
Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E,
Mirimanoff RO: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med 2005, 352:987–996.
14. Hornick JL, Jaffe ES, Fletcher C: Extranodal histiocytic sarcoma.
Clinicopathological analysis of 14 cases of a rare epithelioid malignancy.
Am J Surg Pathol 2004, 28:1133.
15. Wu W, Sayit T, Vinters HV, Pope W, Mirsadraei L, Said J: Primary central
nervous system histiocytic sarcoma presenting as a postradiation
sarcoma: case report and literature review. Hum Pathol 2013, 26.
Epub ahead of print.
doi:10.1186/1752-1947-7-127
Cite this article as: Pérez-Ruiz et al.: Primary leptomeningeal histiocytic
sarcoma in a patient with a good outcome: a case report and review of
the literature. Journal of Medical Case Reports 2013 7:127. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
